ESMO Open最新文献

{"title":"Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy","authors":"V.D. de Jager ,&nbsp;P. Plomp ,&nbsp;M.S. Paats ,&nbsp;S. van Helvert ,&nbsp;A.ter Elst ,&nbsp;A. van den Berg ,&nbsp;H.J. Dubbink ,&nbsp;W.H. van Geffen ,&nbsp;L. Zhang ,&nbsp;L.E.L. Hendriks ,&nbsp;T.J.N. Hiltermann ,&nbsp;B.I. Hiddinga ,&nbsp;L.B.M. Hijmering-Kappelle ,&nbsp;M. Jalving ,&nbsp;J. Kluiver ,&nbsp;B. Koopman ,&nbsp;M. van Kruchten ,&nbsp;E.M.J. van der Logt ,&nbsp;B. Piet ,&nbsp;J. van Putten ,&nbsp;A.J. van der Wekken","doi":"10.1016/j.esmoop.2024.103966","DOIUrl":"10.1016/j.esmoop.2024.103966","url":null,"abstract":"<div><h3>Purpose</h3><div>Molecular tumor boards (MTBs) are considered beneficial for treatment decision making for patients with cancer with uncommon, rare, or complex mutational profiles. The lack of international MTB guidelines results in significant variation in practices and recommendations. Therefore, periodic follow-up is necessary to assess and govern MTB functioning. The objective of this study was to determine the effectiveness of MTB treatment recommendations for patients with rare and complex mutational profiles as implemented in the MTB of the University Medical Center Groningen (UMCG-MTB) in 2019-2020.</div></div><div><h3>Patients and methods</h3><div>A retrospective follow-up study was carried out to determine the clinical outcome of patients with uncommon or rare (combinations of) molecular aberrations for whom targeted therapy was recommended as the next line of treatment by the UMCG-MTB in 2019 and 2020.</div></div><div><h3>Results</h3><div>The UMCG-MTB recommended targeted therapy as the next line of treatment in 132 of 327 patients: 37 in clinical trials, 67 in the on-label setting, and 28 in the off-label setting. For on- and off-label treatment recommendations, congruence of recommended and received treatment was 85% in patients with available follow-up (67/79). Treatment with on-label therapy resulted in a response rate of 50% (21/42), a median progression-free survival (PFS) of 6.3 months [interquartile range (IQR) 2.9-14.9 months], and median overall survival (OS) of 15.8 months (IQR 6.4-34.2 months). Treatment with off-label therapy resulted in a response rate of 53% (8/15), a median PFS of 5.1 months (IQR 1.9-7.3 months), and a median OS of 17.7 months (IQR 5.1-23.7 months).</div></div><div><h3>Conclusion</h3><div>Treatment with MTB-recommended next-line targeted therapy for patients with often heavily pretreated cancer with rare and complex mutational profiles resulted in positive overall responses in over half of patients. Off-label use of targeted therapies, for which there is sufficient rationale as determined by an MTB, is an effective treatment strategy. This study underlines the relevance of discussing patients with rare and complex mutational profiles in an MTB.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 11","pages":"Article 103966"},"PeriodicalIF":7.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PD-L1 thresholds predict efficacy of immune checkpoint inhibition in first-line treatment of advanced gastroesophageal adenocarcinoma. A systematic review and meta-analysis of seven phase III randomized trials","authors":"V. Formica ,&nbsp;C. Morelli ,&nbsp;L. Fornaro ,&nbsp;S. Riondino ,&nbsp;M. Rofei ,&nbsp;E. Fontana ,&nbsp;E.C. Smyth ,&nbsp;M. Roselli ,&nbsp;H.-T. Arkenau","doi":"10.1016/j.esmoop.2024.103967","DOIUrl":"10.1016/j.esmoop.2024.103967","url":null,"abstract":"<div><h3>Background</h3><div>High expression of programmed death-ligand 1 (PD-L1) has been recognized as a marker of improved efficacy of immunotherapy in gastroesophageal adenocarcinoma (GEA); however, the optimal PD-L1 cut-off is still debated. The aim of the present review was to analyze available phase III trials and to identify the appropriate PD-L1 expression cut-off for GEA.</div></div><div><h3>Methods</h3><div>Phase III trials investigating the efficacy of anti-programmed cell death protein 1 (PD-1) therapies in addition to standard chemotherapy versus standard chemotherapy in the first-line setting were selected. Progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) were the analyzed outcome measures. Pooled treatment effects were assessed in the unselected population and in subpopulations with different levels of PD-L1 expression.</div></div><div><h3>Results</h3><div>PD-1 blockade efficacy was found to consistently increase in a linear manner with higher combined positive score (CPS) of PD-L1 expression: pooled hazard ratio (HR) for OS and PFS and pooled odds ratio (OR) for ORR of 0.80, 0.75 and 1.51, respectively, in the unselected population versus 0.67, 0.63 and 1.90, respectively, in the CPS ≥10 population (all <em>P</em> values &lt; 0.0001). In the PD-L1-negative population (CPS &lt;1) a significant benefit of anti-PD-1 agents could not be demonstrated in terms of OS and PFS (<em>P</em> = 0.28 and 0.12, respectively), but it was seen in terms of ORR (<em>P</em> = 0.03). PD-1 blockade was effective in the CPS &lt;10 population (<em>P</em> value for pooled OS HR, PFS HR and response OR are all 0.01), while in the CPS &lt;5 population the effect was of borderline significance for OS (<em>P</em> = 0.07) and significant for PFS and ORR (<em>P</em> = 0.02 and 0.03, respectively).</div></div><div><h3>Conclusion</h3><div>The present meta-analysis confirmed that the benefit of PD-1 blockade in GEA patients is related to PD-L1 CPS, with increased benefit observed for higher CPS cut-offs and no OS benefit in the CPS &lt;1 subset. Overall, data indicate that PD-L1 CPS ≥5 could represent an acceptable cut-off to optimize the risk/benefit ratio of such agents. Our data suggest a potential clinical benefit of immunotherapy in selected patients within the CPS 1-4 population which needs further investigation.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 11","pages":"Article 103967"},"PeriodicalIF":7.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of systemic therapy on clinical T1 small-cell neuroendocrine carcinoma of the bladder","authors":"A.A. Myers ,&nbsp;A.M. Fang ,&nbsp;M.J. Moussa ,&nbsp;H. Hwang ,&nbsp;N.R. Wilson ,&nbsp;M.T. Campbell ,&nbsp;P. Msaouel ,&nbsp;B.H. Lee ,&nbsp;C.C. Guo ,&nbsp;M. Zhang ,&nbsp;J. Zhao ,&nbsp;A.O. Siefker-Radtke ,&nbsp;A.M. Kamat ,&nbsp;O. Alhalabi","doi":"10.1016/j.esmoop.2024.103964","DOIUrl":"10.1016/j.esmoop.2024.103964","url":null,"abstract":"<div><h3>Background</h3><div>The purpose of this study was to analyze survival outcomes and pathologic response of patients with cT1N0 small-cell neuroendocrine carcinoma (SCNEC) of the bladder treated with neoadjuvant chemotherapy (neoCTX).</div></div><div><h3>Materials and methods</h3><div>All cases of bladder SCNEC treated at our institution from January 1996 to July 2023 were identified. cT1N0 was defined as transurethral resection pathology showing lamina propria invasion with present and uninvolved muscularis propria. Pathologic downstaging and recurrences were evaluated. Disease-free survival (DFS) and overall survival (OS) were analyzed using the Cox regression and Kaplan–Meier method.</div></div><div><h3>Results</h3><div>A total of 30 patients with cT1N0 bladder SCNEC were included. Median follow-up was 88 months [95% confidence interval (CI) 44-131 months]. NeoCTX was given to 21 (70%) patients with a median of 4 cycles (range 1-6 cycles). A total of 27 (90%) patients received definitive local therapy. In cT1 bladder SCNEC, neoCTX was associated with decreased odds of pathologic upstaging [odds ratio = 0.07 (95% CI 0.01-0.45), <em>P</em> = 0.004], decreased odds of relapse [odds ratio = 0.12 (95% CI 0.02-0.65), <em>P</em> = 0.01], improved DFS [hazard ratio (HR) 0.30, 95% CI 0.09-0.96, <em>P</em> = 0.04], and improved OS (HR 0.32, 95% CI 0.10-1.02, <em>P</em> = 0.05). Compared with cT2N0 treated with neoCTX, cT1N0 treated with neoCTX had improved median DFS (HR 0.44, 95% CI 0.19-1.03, <em>P</em> = 0.05) and improved median OS (HR 0.52, 95% CI 0.22-1.24, <em>P</em> = 0.14).</div></div><div><h3>Conclusions</h3><div>NeoCTX had suggestive benefit in patients with cT1 bladder SCNEC with decreased odds of pathologic upstaging, metastatic relapse, and improved survival.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 11","pages":"Article 103964"},"PeriodicalIF":7.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disease-free survival as surrogate for overall survival in real-world settings for esophageal cancer: an analysis of SEER-Medicare data","authors":"J.A. Ajani ,&nbsp;L. Leung ,&nbsp;S. Kanters ,&nbsp;P. Singh ,&nbsp;M. Kurt ,&nbsp;I. Kim ,&nbsp;M.-M. Pourrahmat ,&nbsp;H.S. Friedman ,&nbsp;P. Navaratnam ,&nbsp;G. Reardon","doi":"10.1016/j.esmoop.2024.103934","DOIUrl":"10.1016/j.esmoop.2024.103934","url":null,"abstract":"<div><h3>Background</h3><div>Establishing surrogate endpoints for overall survival (OS) may expedite assessment of new therapies in esophageal cancer (EC) and gastroesophageal junction cancer (GEJC). This study aimed to evaluate disease-free survival (DFS) as a surrogate endpoint for OS.</div></div><div><h3>Methods</h3><div>Patients from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database aged ≥66 years with resection after primary diagnosis of stage 2 or 3 EC/GEJC between 2009 and 2017 were analyzed (<em>N</em> = 925; median follow-up 26.2 months). Surrogacy was assessed by evaluating individual level associations between DFS and OS using Spearman’s rank correlation and the association between treatment effects by Pearson’s correlation coefficient. To evaluate the association between treatment effects, patients were classified in synthetic clusters based on treatments received. Propensity score matching addressed imbalances in baseline characteristics between treatment and control groups in the clusters. Predictive performance of the surrogacy equation was assessed internally for the generated clusters via leave-one-out cross-validation and externally via predictions for 26 clinical trials of early-stage EC/GEJC.</div></div><div><h3>Results</h3><div>Patients were mostly male (84%), non-Hispanic white (89.3%), with median age 71.8 years, and cancer stages 2 (50.4%) and 3 (49.6%). Cancer types were adenocarcinoma (76.1%), squamous cell carcinoma (10.4%), and other types (13.5%). Most patients 766/925 (82.8%) received neoadjuvant therapy (680/766 chemoradiotherapy versus 86/766 chemotherapy alone) while 23.6% of the patients received adjuvant therapy. Within each treatment setting, most [705/766 (92.0%) of neoadjuvant therapy and 178/218 (81.7%) of adjuvant therapy] received multi-agent chemotherapy. The individual level correlation was 0.76 (95% confidence interval 0.70-0.80). The correlation between treatment effects was 0.96 (95% confidence interval 0.80-0.99) with a corresponding surrogate threshold effect of 0.71. Both internal (91%) and external (89%) validation of the model demonstrated high predictive accuracy.</div></div><div><h3>Conclusions</h3><div>Correlations between DFS and OS were meaningful at both individual and treatment effect level. The derived surrogacy equation enables reliable early assessments of OS benefit from the observed DFS benefit for early-stage EC/GEJC treatments in real-world settings.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 11","pages":"Article 103934"},"PeriodicalIF":7.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term outcomes of PARP inhibitors in ovarian cancer: survival, adverse events, and post-progression insights","authors":"V. Tuninetti ,&nbsp;J.A. Marín-Jiménez ,&nbsp;G. Valabrega ,&nbsp;E. Ghisoni","doi":"10.1016/j.esmoop.2024.103984","DOIUrl":"10.1016/j.esmoop.2024.103984","url":null,"abstract":"<div><div>Poly-ADP-ribose polymerase inhibitors (PARPis) have revolutionized the management of <em>BRCA</em>-mutated (<em>BRCA</em>^mut) and homologous recombination deficiency (HRD)-positive ovarian cancer (OC). While long-term analyses clearly support the use of PARPi as maintenance therapy after first-line chemotherapy, recent data have raised concerns on detrimental overall survival (OS) in non-<em>BRCA</em>^mut OC, a greater incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), and unfavorable outcomes following subsequent platinum-based chemotherapy in pretreated OC patients. In this report we discuss the long-term follow-up results from phase III trials in pretreated OC patients, which led to the Food and Drug Administration’s withdrawal of PARPi indications in this setting. We summarize the newly available evidence concerning the risk of MDS/AML and the post-progression efficacy results after PARPi. We emphasize the importance of long-term follow-up and real-world data coming from international registries to define the efficacy and safety of stopping PARPi at relapse at a pre-specified time. To this point, biomarkers able to identify the patients who will experience long-term remission with PARPi maintenance or develop early resistance are urgently needed to guide treatment decision and duration.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 11","pages":"Article 103984"},"PeriodicalIF":7.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incorporating immunotherapy in the management of early-stage estrogen receptor-positive breast cancer","authors":"G. Nader-Marta ,&nbsp;A.G. Waks ,&nbsp;S.M. Tolaney ,&nbsp;E.L. Mayer","doi":"10.1016/j.esmoop.2024.103977","DOIUrl":"10.1016/j.esmoop.2024.103977","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 11","pages":"Article 103977"},"PeriodicalIF":7.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What constitutes meaningful benefit of cancer drugs in the context of LMICs? A mixed-methods study of oncologists’ perceptions on endpoints, benefit, price, and value of cancer drugs","authors":"S.S. Datta ,&nbsp;V. Sharma ,&nbsp;A. Mukherjee ,&nbsp;S. Agrawal ,&nbsp;B. Sirohi ,&nbsp;B. Gyawali","doi":"10.1016/j.esmoop.2024.103976","DOIUrl":"10.1016/j.esmoop.2024.103976","url":null,"abstract":"<div><h3>Background</h3><div>The importance of surrogate endpoints, magnitude of clinical benefit of cancer drugs, and their prices have often been debated in the oncology world. No study, however, has systemically explored oncologists’ perception regarding these issues.</div></div><div><h3>Methods</h3><div>We conducted a mixed-methods study including in-depth qualitative interviews of medical oncologists prescribing cancer drug therapy in India. Quantitative data were collected using a predetermined proforma. Qualitative in-depth interviews were audio-recorded, transcribed verbatim, anonymized, subsequently coded, and analyzed by generating basic and global themes.</div></div><div><h3>Results</h3><div>We interviewed 25 medical oncologists. Twenty-eight percent of oncologists rarely used cancer drugs that improved response rate (RR) but not overall survival (OS), and an equal percentage mostly/often used such drugs. For cancer drugs that improved progression-free survival (PFS) but not OS, 20% never/rarely used them while 48% mostly/often used them. Oncologists in India considered a 4.5-month (range, 1.5-12 months) advantage in median PFS as meaningful, and considered price of ∼120 United States Dollars (USD) per month (range, 48-720 USD per month) for those PFS gains as justified. For OS, median gains of 4.5 months (range, 2-24 months) and at a monthly price of ∼360 USD (range, 48-900 USD) was considered justified. Oncologists in India were aware and concerned that RR only meant tumour shrinkage not survival benefit, but many assumed that tumour shrinkage meant better quality of life. Many oncologists acknowledged the limitations of PFS but would use a drug with PFS benefit if it was cheaper than the drug with OS benefit.</div></div><div><h3>Conclusions</h3><div>Oncologists in India showed awareness of the limited surrogacy between RR/PFS and OS but assumed that RR/PFS correlated with improved quality of life and acknowledged price as a factor in deciding treatment choices. This is the first study providing a benchmark for minimum clinical benefit (4.5 months in PFS or OS) and maximum monthly price (120 USD for PFS, 360 USD for OS) deemed justifiable by oncologists practicing in low-and-middle-income countries.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 11","pages":"Article 103976"},"PeriodicalIF":7.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of solid oncology drugs in older patients: a narrative review","authors":"A. Rousseau ,&nbsp;A. Géraud ,&nbsp;R. Geiss ,&nbsp;A. Farcet ,&nbsp;J.-P. Spano ,&nbsp;A.-S. Hamy ,&nbsp;P. Gougis","doi":"10.1016/j.esmoop.2024.103965","DOIUrl":"10.1016/j.esmoop.2024.103965","url":null,"abstract":"<div><div>The older population represents ∼50%-60% of the population of newly diagnosed patients with cancer. Due to physiological and pathological aging and the increased presence of comorbidities and frailty factors, this population is at higher risk of serious toxicity from anticancer drugs and, consequently, often under-treated. Despite the complexity of these treatments, a good knowledge of the pharmacology of anticancer drugs and potentially risky situations can limit the emergence of potentially lethal toxicities in this population. This review focuses on optimizing systemic oncology treatments for older patients, emphasizing the unique characteristics of each therapeutic class and the necessity for a precautionary approach for this vulnerable population.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 11","pages":"Article 103965"},"PeriodicalIF":7.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142552081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognosis prediction with the IHC3 score in patients with node-negative, hormone receptor-positive, HER2-negative early breast cancer","authors":"K. Seitz ,&nbsp;C. Goossens ,&nbsp;H. Huebner ,&nbsp;P. Gass ,&nbsp;S. Uhrig ,&nbsp;F. Heindl ,&nbsp;J. Emons ,&nbsp;M. Ruebner ,&nbsp;D. Anetsberger ,&nbsp;A. Hartmann ,&nbsp;M.W. Beckmann ,&nbsp;R. Erber ,&nbsp;C.C. Hack ,&nbsp;P.A. Fasching ,&nbsp;L. Häberle","doi":"10.1016/j.esmoop.2024.103963","DOIUrl":"10.1016/j.esmoop.2024.103963","url":null,"abstract":"<div><h3>Background</h3><div>Prognostication has been used to identify patient populations that could potentially benefit from treatment de-escalation. In patients with hormone receptor-positive (HRpos), human epidermal growth factor receptor 2-negative (HER2neg) early breast cancer (eBC), treatment de-escalation classically involved omitting chemotherapy. With recently developed specialized therapies that require hands-on side-effect management, the therapeutic landscape is changing and therapy decisions are no longer based only on prognosis, but also consider potential side-effects. Therefore, identification of patient groups based on prognostication has gained importance.</div></div><div><h3>Materials and methods</h3><div>In this retrospective analysis, a population of 2359 node-negative HRpos/HER2neg eBC patients was selected from all patients treated at the University Breast Center of Franconia, Germany between 2002 and 2021. The prognostic value of the IHC3 score (incorporating immunohistochemical measurements of the estrogen and progesterone receptor status and Ki-67) with clinical parameters (lymph node status, tumor stage, grading) regarding invasive disease-free survival (iDFS) and overall survival (OS) was assessed.</div></div><div><h3>Results</h3><div>IHC3 positively correlated with Ki-67 expression and inversely correlated with hormone receptor expression. IHC3 categorized into quartiles identified patients with a more unfavorable prognosis: 5-year and 10-year iDFS rates for patients in the highest versus the lowest quartile were 84% versus 95% and 70% versus 88%, respectively. A sensitivity analysis of distant disease-free survival showed similar results to those of iDFS. Five-year and 10-year OS rates for patients in the highest versus the lowest quartile were, respectively, 92% versus 97% and 81% versus 92%.</div></div><div><h3>Conclusions</h3><div>IHC3 is able to define prognostic groups in patients with node-negative, HRpos/HER2neg eBC. Node-negative patients with a high IHC3 score had the worst prognosis, which was comparable to that of node-positive patients described in recent trials. This simple and cost-effective tool could thus potentially aid in identifying patient groups for innovative therapeutic approaches.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 11","pages":"Article 103963"},"PeriodicalIF":7.1,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142497423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Encorafenib, binimetinib and cetuximab in BRAF V600E-mutated advanced pancreatic adenocarcinoma","authors":"A. Zaanan ,&nbsp;V. Dabout ,&nbsp;S. Garinet ,&nbsp;D. Giraud ,&nbsp;G. Perkins ,&nbsp;J. Taieb ,&nbsp;C. Gallois","doi":"10.1016/j.esmoop.2024.103975","DOIUrl":"10.1016/j.esmoop.2024.103975","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 11","pages":"Article 103975"},"PeriodicalIF":7.1,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142497421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}